From the Laboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892-4256.
From the Laboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892-4256.
J Biol Chem. 2013 Nov 8;288(45):32622-32636. doi: 10.1074/jbc.M113.498980. Epub 2013 Sep 24.
P-glycoprotein (P-gp) is an ATP binding cassette transporter that effluxes a variety of structurally diverse compounds including anticancer drugs. Computational models of human P-gp in the apo- and nucleotide-bound conformation show that the adenine group of ATP forms hydrogen bonds with the conserved Asp-164 and Asp-805 in intracellular loops 1 and 3, respectively, which are located at the interface between the nucleotide binding domains and transmembrane domains. We investigated the role of Asp-164 and Asp-805 residues by substituting them with cysteine in a cysteine-less background. It was observed that the D164C/D805C mutant, when expressed in HeLa cells, led to misprocessing of P-gp, which thus failed to transport the drug substrates. The misfolded protein could be rescued to the cell surface by growing the cells at a lower temperature (27 °C) or by treatment with substrates (cyclosporine A, FK506), modulators (tariquidar), or small corrector molecules. We also show that short term (4-6 h) treatment with 15 μM cyclosporine A or FK506 rescues the pre-formed immature protein trapped in the endoplasmic reticulum in an immunophilin-independent pathway. The intracellularly trapped misprocessed protein associates more with chaperone Hsp70, and the treatment with cyclosporine A reduces the association of mutant P-gp, thus allowing it to be trafficked to the cell surface. The function of rescued cell surface mutant P-gp is similar to that of wild-type protein. These data demonstrate that the Asp-164 and Asp-805 residues are not important for ATP binding, as proposed earlier, but are critical for proper folding and maturation of a functional transporter.
P-糖蛋白(P-gp)是一种 ATP 结合盒转运体,可将多种结构不同的化合物排出,包括抗癌药物。人 P-gp 在apo 和核苷酸结合构象的计算模型表明,ATP 的腺嘌呤基团分别与细胞内环 1 和 3 中的保守天冬氨酸残基 164 和 805 形成氢键,这些残基位于核苷酸结合域和跨膜域之间的界面上。我们通过在无半胱氨酸背景下用半胱氨酸取代 Asp-164 和 Asp-805 残基来研究这些残基的作用。观察到,当在 HeLa 细胞中表达时,D164C/D805C 突变体导致 P-gp 的错误加工,从而无法转运药物底物。通过在较低温度(27°C)下培养细胞或用底物(环孢素 A、FK506)、调节剂(塔里奎达)或小分子校正分子处理,可以将错误折叠的蛋白质挽救到细胞表面。我们还表明,用 15 μM 环孢素 A 或 FK506 短期(4-6 h)处理可挽救被困在内质网中的预形成的不成熟蛋白质,这是一种免疫亲和素非依赖性途径。细胞内被困的错误加工的蛋白质与伴侣 Hsp70 更多地相关,并且环孢素 A 的处理减少了突变 P-gp 的关联,从而允许其被转运到细胞表面。挽救的细胞表面突变 P-gp 的功能与野生型蛋白相似。这些数据表明,如前所述,Asp-164 和 Asp-805 残基对于 ATP 结合不重要,而是对于功能性转运体的正确折叠和成熟至关重要。